Phase 1 SAD/MAD Study of FZ008-145 in Healthy Subjects

Phase 1, randomised, double-blind trial of FZ008-145 in pain (5 arms), sponsored by Fermion Technology. Primary endpoints: Number of adverse events (AEs) and treatment-emergent adverse events (TEAEs) for FZ008-145 solution up to 14 days, Number of adverse events (AEs) and treatment-emergent adverse events (TEAEs) for FZ008-145 tablet up to 14 days and 1 more. Started Nov 2024; status: completed.